share_log

Avid Bioservices (NASDAQ:CDMO) Grows 8.7% This Week, Taking Five-year Gains to 67%

Avid Bioservices (NASDAQ:CDMO) Grows 8.7% This Week, Taking Five-year Gains to 67%

本週Avid bioservices(納斯達克:CDMO)增長了8.7%,五年增長率達67%。
Simply Wall St ·  08/20 07:33

When you buy and hold a stock for the long term, you definitely want it to provide a positive return. Furthermore, you'd generally like to see the share price rise faster than the market. Unfortunately for shareholders, while the Avid Bioservices, Inc. (NASDAQ:CDMO) share price is up 67% in the last five years, that's less than the market return. Unfortunately the share price is down 5.3% in the last year.

當你買入並持有股票長期投資時,你肯定希望它能提供正面回報。此外,你通常希望看到股價上漲速度比市場快。不幸的是,對於股東來說,雖然Avid Bioservices, Inc.(納斯達克:CDMO)股價在過去五年中上漲了67%,但這比市場回報低。更不幸的是,股價在過去一年中下跌了5.3%。

Since the stock has added US$58m to its market cap in the past week alone, let's see if underlying performance has been driving long-term returns.

由於該股票上週市值增加了5800萬美元,所以讓我們看看潛在業績是否推動了長期回報。

Avid Bioservices isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Shareholders of unprofitable companies usually desire strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

Avid Bioservices目前沒有盈利,因此大多數分析師會關注營收增長,以了解該基礎業務增長的速度。不盈利公司的股東通常希望有強勁的營收增長。那是因爲快速的營收增長可以輕鬆推斷出相當大的利潤預測。過去五年,Avid Bioservices的營收每年以21%的速度增長。這遠高於大多數未盈利的公司。雖然股東獲得了利潤,但該期間的11%增幅與整體市場相比並不令人印象深刻。你可以說市場仍然非常懷疑,考慮到營收的增長。股票可能過去被定價過高,但如果你正在尋找被低估的增長股,這些數字表明這裏可能存在機會。

For the last half decade, Avid Bioservices can boast revenue growth at a rate of 21% per year. That's well above most pre-profit companies. It's nice to see shareholders have made a profit, but the gain of 11% over the period isn't that impressive compared to the overall market. You could argue the market is still pretty skeptical, given the growing revenues. It could be that the stock was previously over-priced - but if you're looking for underappreciated growth stocks, these numbers indicate that there might be an opportunity here.

雖然較廣泛的市場在去年上漲了約28%,但Avid Bioservices的股東虧損了5.3%。即使是好股票的股價有時也會下跌,但是在對一個公司進行太多投資之前,我們想要看到業務基本指標的提高。好消息是,長期股東有賺錢,五年來年增長率爲11%。可能最近的拋售是一個機會,因此可能值得檢查基礎數據是否存在長期的增長趨勢。雖然考慮市場情況可能對股價產生不同的影響,但還有其他更重要的因素。例如,承擔風險 - Avid Bioservices有2個警告標誌,我們認爲你需要知道。

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

您可以看到以下收益和營收的變化情況(通過單擊圖像了解精確值)。

big
NasdaqCM:CDMO Earnings and Revenue Growth August 20th 2024
NasdaqCM:CDMO的收益和營業收入增長2024年8月20日

We like that insiders have been buying shares in the last twelve months. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. If you are thinking of buying or selling Avid Bioservices stock, you should check out this free report showing analyst profit forecasts.

我們喜歡近十二個月內內部人士已購買股票的情況。話雖如此,大多數人認爲收益和營收增長趨勢是業務更重要的指導。如果你正在考慮買或賣Avid Bioservices的股票,你應該查看這個免費報告,其中顯示了分析師的利潤預測。

A Different Perspective

不同的觀點

While the broader market gained around 28% in the last year, Avid Bioservices shareholders lost 5.3%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. On the bright side, long term shareholders have made money, with a gain of 11% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Take risks, for example - Avid Bioservices has 2 warning signs we think you should be aware of.

即使較廣泛的市場在去年上漲了約28%,Avid Bioservices的股東仍然虧損了5.3%。即使是好股票的股價有時也會下跌,但在對一個公司進行太多投資之前,我們想要看到業務基本指標的提高。好消息是,長期股東有賺錢,五年來年增長率爲11%。可能最近的拋售是一個機會,因此可能值得檢查基礎數據是否存在長期的增長趨勢。儘管考慮市場情況可能對股價產生不同的影響,但還有其他更重要的因素。例如,承擔風險 - Avid Bioservices有2個警告標誌,我們認爲你需要知道。

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: most of them are flying under the radar).

如果您喜歡與管理層共同購買股票,那麼您可能會喜歡這個免費的公司列表(提示:大多數公司沒有受到關注)。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論